The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.
 
Sarah Verhoeff
No Relationships to Disclose
 
Pim P van de Donk
No Relationships to Disclose
 
Erik H.J.G. Aarntzen
Research Funding - AstraZeneca (Inst)
 
Iris Harriëtte Cornelia Miedema
Travel, Accommodations, Expenses - Roche
 
Sjoukje Oosting
Research Funding - Celldex (Inst)
 
Jens Voortman
Consulting or Advisory Role - MSD Oncology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Ipsen; Merck; Pfizer; Pfizer; Sanofi; TEVA
 
Adrienne H. Brouwers
No Relationships to Disclose
 
Marije Slingerland
No Relationships to Disclose
 
Sandra Heskamp
No Relationships to Disclose
 
Carla M.L.- Van Herpen
Consulting or Advisory Role - Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); MSD (Inst); Regeneron (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Sanofi (Inst)